Since the expression of both Nrf2 and ATF4 transcription factors is associated with poor prognosis and drug resistance in patients with bladder cancers, inhibition of xCT may represent an effective treatment to increase the efficacy of proteasome inhibitors [62]. The gene discussed is SLC7A11; the disease is urinary bladder carcinoma.